Project TitleAndrogen Receptor Inhibitor for Use in Treating Breast Cancer
Track Code2016-035
Short Description

The University of Texas at El Paso seeks a partner for licensing a novel breast cancer treatment (MJC13).


MJC13 is a first-in-class drug for targeting the regulation of androgen receptor (AR) by FKBP52. Through binding a recently identified regulatory surface on AR (BF3), MJC13 prevents the FKBP52-receptor complex from dissociating resulting in the retention of AR in the cytoplasm. Studies have firmly established the androgen receptor as a relevant drug target in subsets of breast cancer patients. Thus, MJC13 holds great promise for the treatment of subsets of breast cancers for which no treatments currently exist.

Tagsandrogen, anit-androgen, biotechnology, breast, cancer, cancer treatment, pharmaceutical, prostate cancer
Posted DateOct 21, 2016 4:50 PM


Marc Cox
Jennifer Richer


Melissa Silverstein


  • Androgen receptor targeted therapy for breast cancer
  • Strong drug safety profile
  • Less adverse side effects
  • Stable intravenous formulation

Potential Applications

  • Breast cancer 
  • Prostate cancer
  • Benign prostatic hyperplasia
  • Contraceptives 
  • Androgen receptor related disorders
  • Glucocorticoid receptor related disorders
  • Progesterone receptor related disorders

Contact Information

For more information, please contact UTEP's Office of Technology Commercialization at or 915-747-8030


File Name Description
One-Pager for 2016-035 None Download

Intellectual Property

Patent Number Issue Date Type Country of Filing
None None Other Patent None